Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential
Background The clinical outcome of appendiceal mucinous neoplasm (AMN) is not well understood. This study aimed to compare the long-term outcome for the uncertain malignant potential (UMP) subtype of AMNs with those of the mucinous adenoma (MA) and mucinous adenocarcinoma (MAC) subtypes. Methods In...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2017-04, Vol.24 (4), p.974-982 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 982 |
|---|---|
| container_issue | 4 |
| container_start_page | 974 |
| container_title | Annals of surgical oncology |
| container_volume | 24 |
| creator | Shin, Rumi Chai, Young Jun Park, Ji Won Chang, Mee soo Bae, Jeong Mo Kim, Min Jung Park, Byung Kwan Park, Kyu Joo Jeong, Seung-Yong |
| description | Background
The clinical outcome of appendiceal mucinous neoplasm (AMN) is not well understood. This study aimed to compare the long-term outcome for the uncertain malignant potential (UMP) subtype of AMNs with those of the mucinous adenoma (MA) and mucinous adenocarcinoma (MAC) subtypes.
Methods
In this study, AMNs were classified into three groups (MA, UMP, and MAC), and clinical characteristics, overall survival (OS), and progression-free survival (PFS) were compared among the three groups.
Results
The study included 65 AMN patients (26 MA, 20 UMP, and 19 MAC patients). The median follow-up period was 87 months (range 0.3–311.0) months. The symptoms at diagnosis and the presence of pseudomyxoma peritonei were more common in the MAC group than in the MA group (
P
= 0.012) or the UMP group (
P
|
| doi_str_mv | 10.1245/s10434-016-5657-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837281698</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1837281698</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-39132040da142ae36f7c252b35e7a799d1a642f53d1bae55e06cc5be43eb5a853</originalsourceid><addsrcrecordid>eNp1kEtLxDAQx4Mo7vr4AF6k4MVLNe-2x2XxBevj4N6EkKZTiaRpbdKD394sqyKCp4SZ3_xn-CF0QvAFoVxcBoI54zkmMhdSFLncQXMiUoXLkuymP5ZlXlEpZugghDeMScGw2EczWpSUSlrN0cvaRdvpCNnSWW-NdtnjFE3fQcj6NlsMA_jGGkj1-8lY308he4B-cDp0G2DtDYxRW5_da2dfvfYxe-oj-Gi1O0J7rXYBjr_eQ7S-vnpe3uarx5u75WKVG1bQmLOKMIo5bjThVAOTbWGooDUTUOiiqhqiJaetYA2pNQgBWBojauAMaqFLwQ7R-TZ3GPv3CUJUnQ0GnNMe0sGKlGlPSWRVJvTsD_rWT6NP1yWq4DJhfBNItpQZ-xBGaNUwJkvjhyJYbdSrrXqV1KuNeiXTzOlX8lR30PxMfLtOAN0CIbX8K4y_Vv-b-glz4446</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1874628145</pqid></control><display><type>article</type><title>Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Shin, Rumi ; Chai, Young Jun ; Park, Ji Won ; Chang, Mee soo ; Bae, Jeong Mo ; Kim, Min Jung ; Park, Byung Kwan ; Park, Kyu Joo ; Jeong, Seung-Yong</creator><creatorcontrib>Shin, Rumi ; Chai, Young Jun ; Park, Ji Won ; Chang, Mee soo ; Bae, Jeong Mo ; Kim, Min Jung ; Park, Byung Kwan ; Park, Kyu Joo ; Jeong, Seung-Yong</creatorcontrib><description>Background
The clinical outcome of appendiceal mucinous neoplasm (AMN) is not well understood. This study aimed to compare the long-term outcome for the uncertain malignant potential (UMP) subtype of AMNs with those of the mucinous adenoma (MA) and mucinous adenocarcinoma (MAC) subtypes.
Methods
In this study, AMNs were classified into three groups (MA, UMP, and MAC), and clinical characteristics, overall survival (OS), and progression-free survival (PFS) were compared among the three groups.
Results
The study included 65 AMN patients (26 MA, 20 UMP, and 19 MAC patients). The median follow-up period was 87 months (range 0.3–311.0) months. The symptoms at diagnosis and the presence of pseudomyxoma peritonei were more common in the MAC group than in the MA group (
P
= 0.012) or the UMP group (
P
< 0.001). The 5-year OS rates were 95.5% for the MA group, 93.8% for the UMP group, and 78.3% for the MAC group (
P
< 0.001), and the 5-year PFS rates were 95.2% for the MA group, 95% for the UMP group, and 36.8% for the MAC group (
P
< 0.001). Thus, OS and PFS did not differ significantly in the MA and UMP groups (
P
= 0.884 and 0.345, respectively). In contrast, the OS and PFS of the MAC group were worse than in the MA group (
P
= 0.017 and <0.001, respectively) or the UMP group (
P
< 0.001 and 0.001, respectively).
Conclusions
The long-term outcome for UMP tumors is similar to that for MA tumors and significantly better than for MAC tumors.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-016-5657-6</identifier><identifier>PMID: 27822629</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adenocarcinoma, Mucinous - secondary ; Adenocarcinoma, Mucinous - surgery ; Adult ; Aged ; Aged, 80 and over ; Appendiceal Neoplasms - pathology ; Appendiceal Neoplasms - surgery ; Clinical outcomes ; Cystadenoma, Mucinous - secondary ; Cystadenoma, Mucinous - surgery ; Disease-Free Survival ; Female ; Follow-Up Studies ; Gastrointestinal Oncology ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local - pathology ; Oncology ; Peritoneal Neoplasms - secondary ; Pseudomyxoma Peritonei - pathology ; Risk Factors ; Surgery ; Surgical Oncology ; Survival Rate ; Time Factors</subject><ispartof>Annals of surgical oncology, 2017-04, Vol.24 (4), p.974-982</ispartof><rights>Society of Surgical Oncology 2016</rights><rights>Annals of Surgical Oncology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-39132040da142ae36f7c252b35e7a799d1a642f53d1bae55e06cc5be43eb5a853</citedby><cites>FETCH-LOGICAL-c372t-39132040da142ae36f7c252b35e7a799d1a642f53d1bae55e06cc5be43eb5a853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-016-5657-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-016-5657-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27822629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shin, Rumi</creatorcontrib><creatorcontrib>Chai, Young Jun</creatorcontrib><creatorcontrib>Park, Ji Won</creatorcontrib><creatorcontrib>Chang, Mee soo</creatorcontrib><creatorcontrib>Bae, Jeong Mo</creatorcontrib><creatorcontrib>Kim, Min Jung</creatorcontrib><creatorcontrib>Park, Byung Kwan</creatorcontrib><creatorcontrib>Park, Kyu Joo</creatorcontrib><creatorcontrib>Jeong, Seung-Yong</creatorcontrib><title>Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
The clinical outcome of appendiceal mucinous neoplasm (AMN) is not well understood. This study aimed to compare the long-term outcome for the uncertain malignant potential (UMP) subtype of AMNs with those of the mucinous adenoma (MA) and mucinous adenocarcinoma (MAC) subtypes.
Methods
In this study, AMNs were classified into three groups (MA, UMP, and MAC), and clinical characteristics, overall survival (OS), and progression-free survival (PFS) were compared among the three groups.
Results
The study included 65 AMN patients (26 MA, 20 UMP, and 19 MAC patients). The median follow-up period was 87 months (range 0.3–311.0) months. The symptoms at diagnosis and the presence of pseudomyxoma peritonei were more common in the MAC group than in the MA group (
P
= 0.012) or the UMP group (
P
< 0.001). The 5-year OS rates were 95.5% for the MA group, 93.8% for the UMP group, and 78.3% for the MAC group (
P
< 0.001), and the 5-year PFS rates were 95.2% for the MA group, 95% for the UMP group, and 36.8% for the MAC group (
P
< 0.001). Thus, OS and PFS did not differ significantly in the MA and UMP groups (
P
= 0.884 and 0.345, respectively). In contrast, the OS and PFS of the MAC group were worse than in the MA group (
P
= 0.017 and <0.001, respectively) or the UMP group (
P
< 0.001 and 0.001, respectively).
Conclusions
The long-term outcome for UMP tumors is similar to that for MA tumors and significantly better than for MAC tumors.</description><subject>Adenocarcinoma, Mucinous - secondary</subject><subject>Adenocarcinoma, Mucinous - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Appendiceal Neoplasms - pathology</subject><subject>Appendiceal Neoplasms - surgery</subject><subject>Clinical outcomes</subject><subject>Cystadenoma, Mucinous - secondary</subject><subject>Cystadenoma, Mucinous - surgery</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastrointestinal Oncology</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Oncology</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Pseudomyxoma Peritonei - pathology</subject><subject>Risk Factors</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Time Factors</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kEtLxDAQx4Mo7vr4AF6k4MVLNe-2x2XxBevj4N6EkKZTiaRpbdKD394sqyKCp4SZ3_xn-CF0QvAFoVxcBoI54zkmMhdSFLncQXMiUoXLkuymP5ZlXlEpZugghDeMScGw2EczWpSUSlrN0cvaRdvpCNnSWW-NdtnjFE3fQcj6NlsMA_jGGkj1-8lY308he4B-cDp0G2DtDYxRW5_da2dfvfYxe-oj-Gi1O0J7rXYBjr_eQ7S-vnpe3uarx5u75WKVG1bQmLOKMIo5bjThVAOTbWGooDUTUOiiqhqiJaetYA2pNQgBWBojauAMaqFLwQ7R-TZ3GPv3CUJUnQ0GnNMe0sGKlGlPSWRVJvTsD_rWT6NP1yWq4DJhfBNItpQZ-xBGaNUwJkvjhyJYbdSrrXqV1KuNeiXTzOlX8lR30PxMfLtOAN0CIbX8K4y_Vv-b-glz4446</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Shin, Rumi</creator><creator>Chai, Young Jun</creator><creator>Park, Ji Won</creator><creator>Chang, Mee soo</creator><creator>Bae, Jeong Mo</creator><creator>Kim, Min Jung</creator><creator>Park, Byung Kwan</creator><creator>Park, Kyu Joo</creator><creator>Jeong, Seung-Yong</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential</title><author>Shin, Rumi ; Chai, Young Jun ; Park, Ji Won ; Chang, Mee soo ; Bae, Jeong Mo ; Kim, Min Jung ; Park, Byung Kwan ; Park, Kyu Joo ; Jeong, Seung-Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-39132040da142ae36f7c252b35e7a799d1a642f53d1bae55e06cc5be43eb5a853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenocarcinoma, Mucinous - secondary</topic><topic>Adenocarcinoma, Mucinous - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Appendiceal Neoplasms - pathology</topic><topic>Appendiceal Neoplasms - surgery</topic><topic>Clinical outcomes</topic><topic>Cystadenoma, Mucinous - secondary</topic><topic>Cystadenoma, Mucinous - surgery</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastrointestinal Oncology</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Oncology</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Pseudomyxoma Peritonei - pathology</topic><topic>Risk Factors</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shin, Rumi</creatorcontrib><creatorcontrib>Chai, Young Jun</creatorcontrib><creatorcontrib>Park, Ji Won</creatorcontrib><creatorcontrib>Chang, Mee soo</creatorcontrib><creatorcontrib>Bae, Jeong Mo</creatorcontrib><creatorcontrib>Kim, Min Jung</creatorcontrib><creatorcontrib>Park, Byung Kwan</creatorcontrib><creatorcontrib>Park, Kyu Joo</creatorcontrib><creatorcontrib>Jeong, Seung-Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shin, Rumi</au><au>Chai, Young Jun</au><au>Park, Ji Won</au><au>Chang, Mee soo</au><au>Bae, Jeong Mo</au><au>Kim, Min Jung</au><au>Park, Byung Kwan</au><au>Park, Kyu Joo</au><au>Jeong, Seung-Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>24</volume><issue>4</issue><spage>974</spage><epage>982</epage><pages>974-982</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
The clinical outcome of appendiceal mucinous neoplasm (AMN) is not well understood. This study aimed to compare the long-term outcome for the uncertain malignant potential (UMP) subtype of AMNs with those of the mucinous adenoma (MA) and mucinous adenocarcinoma (MAC) subtypes.
Methods
In this study, AMNs were classified into three groups (MA, UMP, and MAC), and clinical characteristics, overall survival (OS), and progression-free survival (PFS) were compared among the three groups.
Results
The study included 65 AMN patients (26 MA, 20 UMP, and 19 MAC patients). The median follow-up period was 87 months (range 0.3–311.0) months. The symptoms at diagnosis and the presence of pseudomyxoma peritonei were more common in the MAC group than in the MA group (
P
= 0.012) or the UMP group (
P
< 0.001). The 5-year OS rates were 95.5% for the MA group, 93.8% for the UMP group, and 78.3% for the MAC group (
P
< 0.001), and the 5-year PFS rates were 95.2% for the MA group, 95% for the UMP group, and 36.8% for the MAC group (
P
< 0.001). Thus, OS and PFS did not differ significantly in the MA and UMP groups (
P
= 0.884 and 0.345, respectively). In contrast, the OS and PFS of the MAC group were worse than in the MA group (
P
= 0.017 and <0.001, respectively) or the UMP group (
P
< 0.001 and 0.001, respectively).
Conclusions
The long-term outcome for UMP tumors is similar to that for MA tumors and significantly better than for MAC tumors.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>27822629</pmid><doi>10.1245/s10434-016-5657-6</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2017-04, Vol.24 (4), p.974-982 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1837281698 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adenocarcinoma, Mucinous - secondary Adenocarcinoma, Mucinous - surgery Adult Aged Aged, 80 and over Appendiceal Neoplasms - pathology Appendiceal Neoplasms - surgery Clinical outcomes Cystadenoma, Mucinous - secondary Cystadenoma, Mucinous - surgery Disease-Free Survival Female Follow-Up Studies Gastrointestinal Oncology Humans Male Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - pathology Oncology Peritoneal Neoplasms - secondary Pseudomyxoma Peritonei - pathology Risk Factors Surgery Surgical Oncology Survival Rate Time Factors |
| title | Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T20%3A47%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ultimate%20Clinical%20Outcomes%20of%20Appendiceal%20Mucinous%20Neoplasm%20of%20Uncertain%20Malignant%20Potential&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Shin,%20Rumi&rft.date=2017-04-01&rft.volume=24&rft.issue=4&rft.spage=974&rft.epage=982&rft.pages=974-982&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-016-5657-6&rft_dat=%3Cproquest_cross%3E1837281698%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1874628145&rft_id=info:pmid/27822629&rfr_iscdi=true |